Hexima Investor Updates
Closing Share Price at 30 June 2017read more
Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here.
Upcoming Event: Tuesday 25th July at 11.30am at Lvl 38, 88 Phillip Street Sydney (offices of Bell Potter).read more
Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.read more
Hexima Interim Financial Report 31 Dec 16
Presentations and Results from the 2016 Hexima Limited Annual General Meeting
NOTICE IS GIVEN that the Annual General Meeting of the ordinary shareholders of Hexima Limited